

## SEQUENCE LISTING

&lt;110&gt; KS Biomedix Ltd

&lt;120&gt; ANTIBODIES

&lt;130&gt; rep05827wo

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 4

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 363

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Antibody  
Fragment

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(363)

&lt;400&gt; 1

cag	gtg	cag	ctg	cag	gag	tcg	gga	ccc	agc	ctg	gtg	aag	ccc	tca	cag	48
Gln	Val	Gln	Leu	Gln	Glu	Ser	Gly	Pro	Ser	Leu	Val	Lys	Pro	Ser	Gln	
1				5				10					15			

acc	ctc	tcc	ctc	acc	tgc	acg	gtc	tct	gga	ttc	tca	tta	acc	aag	tat	96
Thr	Leu	Ser	Leu	Thr	Cys	Thr	Val	Ser	Gly	Phe	Ser	Leu	Thr	Lys	Tyr	
			20					25					30			

ggt	gtt	agt	tgg	gtc	cgc	cag	gct	cca	gga	aag	gcg	ctt	gag	tgg	cta	144
Gly	Val	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Ala	Leu	Glu	Trp	Leu	
			35				40						45			

ggt	ggt	gtg	tcc	agt	ggt	gca	cta	aca	gcc	tat	aac	aca	gcc	cta	cag	192
Gly	Gly	Val	Ser	Ser	Gly	Ala	Leu	Thr	Ala	Tyr	Asn	Thr	Ala	Leu	Gln	
		50				55					60					

tcc	cga	ctc	agc	gtc	acc	agg	gac	acc	tcc	aag	agc	caa	ttc	tcc	ctg	240
Ser	Arg	Leu	Ser	Val	Thr	Arg	Asp	Thr	Ser	Lys	Ser	Gln	Phe	Ser	Leu	
65					70					75					80	

tca ctg agc agc gtg act act gag gac acg gcc att tac tac tgt gcg 288  
 Ser Leu Ser Ser Val Thr Thr Glu Asp Thr Ala Ile Tyr Tyr Cys Ala  
                     85                    90                    95

aaa tct gtc aat ggt gac agt gtt cct tat ggt ttg gac tac tgg agc 336  
 Lys Ser Val Asn Gly Asp Ser Val Pro Tyr Gly Leu Asp Tyr Trp Ser  
                     100                    105                    110

cca gga ctc cta ctc acc gtc tcc tca 363  
 Pro Gly Leu Leu Leu Thr Val Ser Ser  
                     115                    120

<210> 2

<211> 121

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Antibody  
 Fragment

<400> 2

Gln Val Gln Leu Gln Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln  
                     1                    5                    10                    15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Lys Tyr  
                     20                    25                    30

Gly Val Ser Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Leu  
                     35                    40                    45

Gly Gly Val Ser Ser Gly Ala Leu Thr Ala Tyr Asn Thr Ala Leu Gln  
                     50                    55                    60

Ser Arg Leu Ser Val Thr Arg Asp Thr Ser Lys Ser Gln Phe Ser Leu  
                     65                    70                    75                    80

Ser Leu Ser Ser Val Thr Thr Glu Asp Thr Ala Ile Tyr Tyr Cys Ala  
                     85                    90                    95

Lys Ser Val Asn Gly Asp Ser Val Pro Tyr Gly Leu Asp Tyr Trp Ser  
                     100                    105                    110

Pro Gly Leu Leu Leu Thr Val Ser Ser  
                     115                    120

&lt;210&gt; 3

&lt;211&gt; 333

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Antibody  
Fragment

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(333)

&lt;400&gt; 3

cag	gat	gtg	ctg	act	cag	ccg	tcc	tcc	gtg	tct	ggg	tcc	ctg	ggc	cag	48
Gln	Asp	Val	Leu	Thr	Gln	Pro	Ser	Ser	Val	Ser	Gly	Ser	Leu	Gly	Gln	
1				5					10					15		

agg	gtc	tcc	atc	acc	tgc	tct	gga	agc	agc	agc	aac	att	gga	ggt	aat	96
Arg	Val	Ser	Ile	Thr	Cys	Ser	Gly	Ser	Ser	Ser	Asn	Ile	Gly	Gly	Asn	
			20				25						30			

gct	tat	gtg	ggc	tgg	tac	caa	cag	gtc	cca	gga	tca	gcc	ccc	aga	ctc	144
Ala	Tyr	Val	Gly	Trp	Tyr	Gln	Gln	Val	Pro	Gly	Ser	Ala	Pro	Arg	Leu	
		35				40						45				

ctc	atc	agt	gct	aca	acc	gat	cga	gcc	tcg	ggg	atc	ccc	gac	cga	ttc	192
Leu	Ile	Ser	Ala	Thr	Thr	Asp	Arg	Ala	Ser	Gly	Ile	Pro	Asp	Arg	Phe	
	50					55					60					

tcc	ggc	tcc	agg	tct	ggg	aac	aca	gcc	acc	ctg	acc	atc	agc	tcg	ctc	240
Ser	Gly	Ser	Arg	Ser	Gly	Asn	Thr	Ala	Thr	Leu	Thr	Ile	Ser	Ser	Leu	
65					70					75					80	

cag	gct	gag	gac	gag	gcc	gat	tat	tac	tgt	gca	tcg	tat	caa	agt	act	288
Gln	Ala	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Ala	Ser	Tyr	Gln	Ser	Thr	
			85						90					95		

tac	agt	ggt	gtt	ttc	ggc	agc	ggg	acc	agg	ctg	acc	gtc	ctg	ggt		333
Tyr	Ser	Gly	Val	Phe	Gly	Ser	Gly	Thr	Arg	Leu	Thr	Val	Leu	Gly		
			100					105					110			

&lt;210&gt; 4

&lt;211&gt; 111

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;223&gt; Description of Artificial Sequence:Antibody

## Fragment

&lt;400&gt; 4

Gln Asp Val Leu Thr Gln Pro Ser Ser Val Ser Gly Ser Leu Gly Gln

1 5 10 15

Arg Val Ser Ile Thr Cys Ser Gly Ser Ser Ser Asn Ile Gly Gly Asn

20 25 30

Ala Tyr Val Gly Trp Tyr Gln Gln Val Pro Gly Ser Ala Pro Arg Leu

35 40 45

Leu Ile Ser Ala Thr Thr Asp Arg Ala Ser Gly Ile Pro Asp Arg Phe

50 55 60

Ser Gly Ser Arg Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Ser Leu

65 70 75 80

Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr Gln Ser Thr

85 90 95

Tyr Ser Gly Val Phe Gly Ser Gly Thr Arg Leu Thr Val Leu Gly

100 105 110

comprising the amino acid sequence defined in SEQ ID No. 4, or a variant thereof.

9. A polynucleotide molecule encoding an antibody according to claim 8, wherein the polynucleotide comprises  
5 a nucleotide sequence defined in SEQ ID Nos. 1 and 3, or a variant thereof.

10. A cloning vehicle comprising the polynucleotide molecule according to claim 9.